Disc Medicine, Inc.

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
55.95 ^USD	-21.91%		-29.82%	-29.54%

Feb. 13	Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval	DJ
Feb. 13	Disc Medicine receives complete response letter from FDA for bitopertin for the treatment of EPP	RE

Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents

Published on 01/15/2026 at 06:03 am EST

Reuters

Latest news about Disc Medicine, Inc.

Feb. 13	Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval	DJ
Feb. 13	Disc Medicine receives complete response letter from FDA for bitopertin for the treatment of EPP	RE
Feb. 13	Disc Medicine Drug Bitopertin Receives FDA Response	MT
Feb. 13	US FDA declines to approve Disc Medicine's rare disease drug	RE
Feb. 13	Disc Medicine, Inc. Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP	CI
Jan. 15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jan. 15	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT
Jan. 15	European Stocks Close Mostly Higher in Thursday Trading; GDP Expands in Germany, UK	MT
Jan. 15	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
Jan. 15	Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues	MT
Jan. 15	US FDA delays two drug reviews in new voucher program after safety, efficacy concerns	RE
Jan. 15	Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents	RE
Jan. 14	Disc Medicine, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:00 PM
Jan. 12	Disc Medicine Inc Appoints Lisa Amaya Price as Chief Human Resources Officer	CI
Dec. 17	Disc Medicine Insider Sold Shares Worth $16,858,639, According to a Recent SEC Filing	MT

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Employees

142

Sector

Biotechnology & Medical Research

Calendar

Mar. 26 - Q4 2025 Earnings Release (Projected)

More about the company